Bronchiectasis: Clinical Trials

15 trials for Bronchiectasis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

15 completed. 15 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 315Completed 15

Follow Bronchiectasis: new trials by email Literature Review of Bronchiectasis trials Research Report on Bronchiectasis

Trials (filtered) newest first · largest first

All 15 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Randomised Open Label Trial of Hypertonic Saline and Carbocisteine in Bronchiectasis (CLEAR)
Hypertonic saline, Carbocysteine 750 MG - Bronchiectasis
Phase 3CompletedBelfast Health and Social Care Trust2882018-06-272025-05-02
Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis
Roflumilast, Placebo - Exacerbation Copd, Bronchiectasis
Phase 3CompletedPrince of Songkla University402015-01-012019-10-10
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Ciprofloxacin (BAYQ3939) dry powder for inhalation, Placebo - Bronchiectasis
Phase 3CompletedBayer5212014-04-302017-10-02
Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)
Ciprofloxacin dispersion for inhalation, Placebo - Non Cystic Fibrosis Bronchiectasis
Phase 3CompletedAradigm Corporation2782014-03-312021-03-26
Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Ciprofloxacin DPI (BAYQ3939), Placebo - Bronchiectasis
Phase 3CompletedBayer4162013-05-022018-01-24
Prevention of Bronchiectasis in Infants With Cystic Fibrosis
Azithromycin, Placebo control - Cystic Fibrosis, Bronchiectasis
Phase 3CompletedThe University of Queensland1302012-04-012021-09-16
Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis
AZLI, Placebo - Bronchiectasis
Phase 3CompletedGilead Sciences2662011-04-012014-04-16
Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis
AZLI, Placebo - Bronchiectasis
Phase 3CompletedGilead Sciences2742011-04-012014-04-16
Effects of Roxithromycin on Quality of Life and Physiological Outcomes in Bronchiectasis
Roxithromycin 300 MG, Placebo - Quality of Life, Respiratory Function Tests
Phase 3CompletedPrince of Songkla University402011-03-012019-10-14
Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis
Inhaled mannitol, Matched control - Bronchiectasis
Phase 3CompletedSyntara4852009-11-012016-04-29
Bronchiectasis and Long Term Azithromycin Treatment
Azithromycin, Placebo - Bronchiectasis, Inflammation
Phase 3CompletedW.G.Boersma722008-04-012020-05-28
The Long Term Effect of Inhaled Hypertonic Saline (6%) in Patients With Non Cystic Fibrosis Bronchiectasis
Hypertonic saline 6% - - Bronchiectasis
Phase 3CompletedThe Alfred402007-12-012011-06-23
Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG1321001 in Chronic Cougher
AG1321001(drug) - Cough
Phase 3CompletedAhn-Gook Pharmaceuticals Co.,Ltd3962006-03-012009-07-02
Safety and Efficacy of Bronchitol in Bronchiectasis
Mannitol, placebo - Bronchiectasis
Phase 3CompletedSyntara3542006-03-012008-08-29
EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection
Placebo, EZ-2053, EZ-2053 5mg/kg - Chronic Obstructive Pulmonary, Idiopathic Pulmonary Fibrosis
Phase 3CompletedNeovii Biotech2232005-01-012012-06-11

Narrower conditions

Cystic Fibrosis (2)  ·  Bronchitis, Chronic (1)  ·  Cough (1)  ·  Gastroesophageal Reflux (1)  ·  Idiopathic Pulmonary Fibrosis (1)  ·  Inflammation (1)  ·  Respiratory Insufficiency (1)  ·  upper airway cough syndrome (1)

Broader conditions

Bronchial Diseases (15)  ·  Respiratory Tract Diseases (15)  ·  Digestive System Diseases (3)  ·  Lung Diseases (3)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Genetic Diseases, Inborn (2)  ·  Infant, Newborn, Diseases (2)  ·  Pancreatic Diseases (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Respiration Disorders (2)  ·  Bronchitis (1)  ·  Chronic Disease (1)  ·  Deglutition Disorders (1)  ·  Disease Attributes (1)

Interventions

Azithromycin (2)  ·  Inhalation (2)  ·  Carbocysteine (1)  ·  Case-Control Studies (1)  ·  Ciprofloxacin (1)  ·  Mannitol (1)  ·  Roflumilast (1)  ·  Roxithromycin (1)  ·  Saline Solution, Hypertonic (1)  ·  Sodium Chloride (1)

Sponsors

Bayer (2)  ·  Gilead Sciences (2)  ·  Prince of Songkla University (2)  ·  Syntara (2)  ·  Ahn-Gook Pharmaceuticals Co.,Ltd (1)  ·  Aradigm Corporation (1)  ·  Belfast Health and Social Care Trust (1)  ·  Neovii Biotech (1)  ·  The Alfred (1)  ·  The University of Queensland (1)  ·  W.G.Boersma (1)

Countries

Australia (10)  ·  United States (7)  ·  United Kingdom (6)  ·  Germany (5)  ·  Canada (4)  ·  Netherlands (4)  ·  New Zealand (4)  ·  Argentina (3)  ·  Italy (3)  ·  Latvia (3)  ·  South Korea (3)  ·  Spain (3)  ·  Austria (2)  ·  Belgium (2)  ·  France (2)

Top investigators

Alan Barker, MD (2)  ·  Kanung Saejiam, MS (2)  ·  Anne Holland, PhD, BAppSc (1)  ·  Anne O'Donnell, MD (1)  ·  Brett Charlton (1)  ·  Caroline H Nicolson, MPhysio (1)  ·  Choon-Taek Lee, MD, PhD (1)  ·  Chul-min Ahn, MD, PhD (1)  ·  Diana Bilton, MD (1)  ·  Greg Tino, MD (1)  ·  Hee-Soon Chung, MD, PhD (1)  ·  J. Stuart Elborn (1)  ·  Joon Chang, MD, PhD (1)

Results publications

PMID 25154045, PMID 28495619, PMID 22349069, PMID 23429964, PMID 23532241, PMID 25246664, PMID 29371383, PMID 29371384, PMID 30658914, PMID 32554534, PMID 34974413, PMID 35662406